Peritonealis carcinomatosis okozó recidív inflammatoricus myofibroblastos sarcoma miatt végzett citoreduktív sebészi beavatkozás és intraoperatív intraperitonealis kemohipertermia. Irodalmi áttekintés és esetismertetés

Translated title of the contribution: Cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion for peritoneal carcinomatosis caused by recurrent inflammatory myofibroblastic sarcoma: A case report and review of the literature

Zoltán Mátrai, Gábor Péley, Tibor Kovács, Ferenc Rényi Vámos, Edit Szívós, Eszter Szabó, Ildikó Vereczkey, Klára Török, I. Köves

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Peritoneal carcinomatosis is a fatal diagnosis, associated with poor prognosis and quality of life. Survival is usually estimated in month. Traditionally surgery for peritoneal carcinomatosis was indicated only for palliative effort. Advances in tumour biology, cytoreductive surgery and pharmacology have improved the approach for this condition. An agressive combined approach to peritoneal surface malignancy involves peritonectomy and intraperitoneal perioperative hyperthermic chemotherapy. Cytoreductive surgery reduces carcinomatosis to microscopic residual disease so that intraperitoneal hyperthermic chemotherapy is able to eradicate cancer. Hyperthermic chemotherapy enhances the cytotoxicity of the drugs and increases their penetration into the cancerous tissue. Careful patient selection is crucial for this multy-modality approach. Quantitative prognostic indicators are useful in the assessment of outcome, like peritoneal cancer index and completeness of cytoreduction score. Cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy improves survival but is associated with significant morbidity and mortality. This review is based on a case report of a 22-year-old female patient who had peritoneal carcinomatosis of inflammatory myofibroblastic sarcoma and was treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy at our department.

Original languageHungarian
Pages (from-to)147-158
Number of pages12
JournalOrvosi Hetilap
Volume147
Issue number4
Publication statusPublished - Jan 29 2006

Fingerprint

Sarcoma
Carcinoma
Drug Therapy
Neoplasms
Survival
Patient Selection
Quality of Life
Outcome Assessment (Health Care)
Pharmacology
Morbidity
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Peritonealis carcinomatosis okozó recidív inflammatoricus myofibroblastos sarcoma miatt végzett citoreduktív sebészi beavatkozás és intraoperatív intraperitonealis kemohipertermia. Irodalmi áttekintés és esetismertetés. / Mátrai, Zoltán; Péley, Gábor; Kovács, Tibor; Rényi Vámos, Ferenc; Szívós, Edit; Szabó, Eszter; Vereczkey, Ildikó; Török, Klára; Köves, I.

In: Orvosi Hetilap, Vol. 147, No. 4, 29.01.2006, p. 147-158.

Research output: Contribution to journalArticle

Mátrai, Zoltán ; Péley, Gábor ; Kovács, Tibor ; Rényi Vámos, Ferenc ; Szívós, Edit ; Szabó, Eszter ; Vereczkey, Ildikó ; Török, Klára ; Köves, I. / Peritonealis carcinomatosis okozó recidív inflammatoricus myofibroblastos sarcoma miatt végzett citoreduktív sebészi beavatkozás és intraoperatív intraperitonealis kemohipertermia. Irodalmi áttekintés és esetismertetés. In: Orvosi Hetilap. 2006 ; Vol. 147, No. 4. pp. 147-158.
@article{28ae8a80e79d486cbb50a933f8ac7d5c,
title = "Peritonealis carcinomatosis okoz{\'o} recid{\'i}v inflammatoricus myofibroblastos sarcoma miatt v{\'e}gzett citoredukt{\'i}v seb{\'e}szi beavatkoz{\'a}s {\'e}s intraoperat{\'i}v intraperitonealis kemohipertermia. Irodalmi {\'a}ttekint{\'e}s {\'e}s esetismertet{\'e}s",
abstract = "Peritoneal carcinomatosis is a fatal diagnosis, associated with poor prognosis and quality of life. Survival is usually estimated in month. Traditionally surgery for peritoneal carcinomatosis was indicated only for palliative effort. Advances in tumour biology, cytoreductive surgery and pharmacology have improved the approach for this condition. An agressive combined approach to peritoneal surface malignancy involves peritonectomy and intraperitoneal perioperative hyperthermic chemotherapy. Cytoreductive surgery reduces carcinomatosis to microscopic residual disease so that intraperitoneal hyperthermic chemotherapy is able to eradicate cancer. Hyperthermic chemotherapy enhances the cytotoxicity of the drugs and increases their penetration into the cancerous tissue. Careful patient selection is crucial for this multy-modality approach. Quantitative prognostic indicators are useful in the assessment of outcome, like peritoneal cancer index and completeness of cytoreduction score. Cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy improves survival but is associated with significant morbidity and mortality. This review is based on a case report of a 22-year-old female patient who had peritoneal carcinomatosis of inflammatory myofibroblastic sarcoma and was treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy at our department.",
keywords = "Cytoreductive surgery, Inflammatory myofibroblastic sarcoma, Intraoperative intraperitoneal hyperthermic chemotherapy",
author = "Zolt{\'a}n M{\'a}trai and G{\'a}bor P{\'e}ley and Tibor Kov{\'a}cs and {R{\'e}nyi V{\'a}mos}, Ferenc and Edit Sz{\'i}v{\'o}s and Eszter Szab{\'o} and Ildik{\'o} Vereczkey and Kl{\'a}ra T{\"o}r{\"o}k and I. K{\"o}ves",
year = "2006",
month = "1",
day = "29",
language = "Hungarian",
volume = "147",
pages = "147--158",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "4",

}

TY - JOUR

T1 - Peritonealis carcinomatosis okozó recidív inflammatoricus myofibroblastos sarcoma miatt végzett citoreduktív sebészi beavatkozás és intraoperatív intraperitonealis kemohipertermia. Irodalmi áttekintés és esetismertetés

AU - Mátrai, Zoltán

AU - Péley, Gábor

AU - Kovács, Tibor

AU - Rényi Vámos, Ferenc

AU - Szívós, Edit

AU - Szabó, Eszter

AU - Vereczkey, Ildikó

AU - Török, Klára

AU - Köves, I.

PY - 2006/1/29

Y1 - 2006/1/29

N2 - Peritoneal carcinomatosis is a fatal diagnosis, associated with poor prognosis and quality of life. Survival is usually estimated in month. Traditionally surgery for peritoneal carcinomatosis was indicated only for palliative effort. Advances in tumour biology, cytoreductive surgery and pharmacology have improved the approach for this condition. An agressive combined approach to peritoneal surface malignancy involves peritonectomy and intraperitoneal perioperative hyperthermic chemotherapy. Cytoreductive surgery reduces carcinomatosis to microscopic residual disease so that intraperitoneal hyperthermic chemotherapy is able to eradicate cancer. Hyperthermic chemotherapy enhances the cytotoxicity of the drugs and increases their penetration into the cancerous tissue. Careful patient selection is crucial for this multy-modality approach. Quantitative prognostic indicators are useful in the assessment of outcome, like peritoneal cancer index and completeness of cytoreduction score. Cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy improves survival but is associated with significant morbidity and mortality. This review is based on a case report of a 22-year-old female patient who had peritoneal carcinomatosis of inflammatory myofibroblastic sarcoma and was treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy at our department.

AB - Peritoneal carcinomatosis is a fatal diagnosis, associated with poor prognosis and quality of life. Survival is usually estimated in month. Traditionally surgery for peritoneal carcinomatosis was indicated only for palliative effort. Advances in tumour biology, cytoreductive surgery and pharmacology have improved the approach for this condition. An agressive combined approach to peritoneal surface malignancy involves peritonectomy and intraperitoneal perioperative hyperthermic chemotherapy. Cytoreductive surgery reduces carcinomatosis to microscopic residual disease so that intraperitoneal hyperthermic chemotherapy is able to eradicate cancer. Hyperthermic chemotherapy enhances the cytotoxicity of the drugs and increases their penetration into the cancerous tissue. Careful patient selection is crucial for this multy-modality approach. Quantitative prognostic indicators are useful in the assessment of outcome, like peritoneal cancer index and completeness of cytoreduction score. Cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy improves survival but is associated with significant morbidity and mortality. This review is based on a case report of a 22-year-old female patient who had peritoneal carcinomatosis of inflammatory myofibroblastic sarcoma and was treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy at our department.

KW - Cytoreductive surgery

KW - Inflammatory myofibroblastic sarcoma

KW - Intraoperative intraperitoneal hyperthermic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=33645645487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645645487&partnerID=8YFLogxK

M3 - Article

VL - 147

SP - 147

EP - 158

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 4

ER -